Skip to main content
MedVellum
MCQsExamsAtlas
DashboardPricing
MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳

MedVellum.

The folio

Exam-exhaustive medical education across every specialty — evidence-graded topics, engraved plates, and practice in every written and oral format. Educational content only — not medical advice.

llms.txt · psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship
  • Paediatrics Fellowship
  • Physician Medicine

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Folio edition · Set in Instrument Serif & Archivo

Phys Vivasdermatological

Phys Vivas · dermatological

Genodermatoses with Systemic Significance — Viva Defence

DCE viva defence for Genodermatoses with Systemic Significance.

On this page & tools

Target exams

FRACP DCEMRCP PACES

Target exams

FRACP DCEMRCP PACES
Prompt
DCE viva defence for Genodermatoses with Systemic Significance.

Genodermatoses with Systemic Significance Viva

Long Case Viva Defence

Opening statement

"This patient presents with a problem best framed as Genodermatoses with Systemic Significance. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]

Examiner questions

Q1: "What makes this urgent?" [1]

"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]

Q2: "What is your first investigation package?" [2]

"I order tests that change management now, not a scattergun panel." [1] [2]

Q3: "Walk me through treatment." [1]

"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]

Q4: "What is the classic trap?" [2]

"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]

Short case

Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]

References

  1. [1]Wagner RN, Piñón Hofbauer J, Wally V, Kofler B, et al. Epigenetic and metabolic regulation of epidermal homeostasis Exp Dermatol, 2021.PMID 33600038
  2. [2]Youssefian L, Vahidnezhad H, Touati A, Ziaee V, et al. The genetic basis of hyaline fibromatosis syndrome in patients from a consanguineous background: a case series BMC Med Genet, 2018.PMID 29801470
  3. [3]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
  4. [4]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922
  5. [5]Hajiaqaei M, Mohammadi A Transcranial random noise stimulation (tRNS) over the left dorsolateral prefrontal cortex ameliorates emotion dysregulation and executive function: a single-blind, randomized, sham-controlled clinical trial BMC Psychol, 2026.PMID 42469906
  6. [6]Aw Hashi MO, Derie AM, Ahmed SI Lamellar Ichthyosis in a Resource-Limited Setting: A Somaliland Case Report Int Med Case Rep J, 2026.PMID 41940243
  7. [7]Boitez P, Farges D, Descamps M, Bournazel V, et al. The first year of treatment with selumetinib for NF1-related plexiform neurofibroma is medically challenging in real-life settings Ann Dermatol Venereol, 2026.PMID 41411884
  8. [8]Rossignol J, Bouillet L, Bulai-Livideanu C, Barete S, et al. Diagnosis, management and the burden of symptoms of mastocytosis from the physician's perspective: A nationwide study Br J Haematol, 2025.PMID 40930805